OREANDA-NEWS. Vaccination with the Russian drug "Sputnik V", and then revaccination with a nasal drug, is likely to provide full protection not only from the severe course of COVID-19, but also from infection with coronavirus in principle, Alexander Gintsburg, director of the Gamaleya National Research Center for Epidemiology and Microbiology, told RIA Novosti.

"We assume, although this will need to be studied during clinical trials, that such immunity will be sterile, that is, the vaccinated person will have not only humoral, but also mucosal immunity at the level of the entrance gate," he said.

According to the head of the research institute, thanks to this method of administering the drug, an "independent barrier" is created that prevents the penetration of the virus.

In August 2020, the Ministry of Health registered the world's first vaccine for the prevention of COVID-19, developed by the Gamaleya Research Center for Electrochemistry, Sputnik V, or GamKovidVak. It is widely used, although the preparations of the Novosibirsk center "Vector" ("EpiVacCorona") and the Center named after M. P. Chumakov ("KoviVac") are also available to Russians, several more developments are underway.

Federation Council Speaker Valentina Matvienko said earlier that the doctor advised her to have a nasal vaccine as additional protection. She added that this type of immunization is ineffective without a basic vaccination.